Purpose Metabolic dysregulation has been implicated as a molecular driver of breast cancer in preclinical studies, especially with respect to metastases. We hypothesized that abnormalities in patient metabolism, such as obesity and diabetes, may drive outcomes in breast cancer patients with brain metastases. Methods We retrospectively identified 84 consecutive patients with brain metastases from breast cancer treated with intracranial radiation therapy. Radiation was delivered as whole-brain radiation to a median dose of 3000 cGy or stereotactic radiosurgery to a median dose of 2100 cGy. Kaplan Meier curves were generated for overall survival (OS) data and MantelCox regression was performed to detect differences in groups. Results At analysis, 81 survival events had occurred and the median OS for the entire cohort was 21.7 months. Despite similar modified graded prognostic assessments, resection rates, and receptor status, BMI ≥ 25 kg/m 2 (n = 45) was associated with decreased median OS (13.7 vs. 30.6 months; p < 0.001) and median intracranial progression-free survival (PFS) (7.4 vs. 10.9 months; p = 0.04) compared to patients with BMI < 25 kg/m 2 (n = 39). Similar trends were observed among all three types of breast cancer. Patients with diabetes (n = 17) had decreased median OS (11.8 vs. 26.2 months; p < 0.001) and median intracranial PFS (4.5 vs. 10.3 months; p = 0.001) compared to non-diabetics (n = 67). On multivariate analysis, both BMI ≥ 25 kg/m 2 [HR 2.35 (1.39-3.98); p = 0.002] and diabetes ); p = 0.002] were associated with increased mortality. Conclusions Elevated BMI or diabetes may negatively impact both overall survival and local control in patients with brain metastases from breast cancer, highlighting the importance of the translational development of therapeutic metabolic interventions. Given its prognostic significance, BMI should be used as a stratification in future clinical trial design in this patient population.
Introduction
Among women, breast cancer is the most common malignancy as well as the most common cause of brain metastases [1] . As many as 30% of women with breast cancer develop brain metastases, and the incidence of brain metastases from breast cancer (BMBC) has increased two-to three-fold in recent decades [2] . Improvements in overall survival (OS) for patients with breast cancer have largely been a function of earlier detection and improved extra-cranial disease control [3] . Penetration of the blood-brain barrier and central nervous system (CNS) efficacy is limited to a select few systemic therapies, and BMBC portends a dismal prognosis and is capable of inflicting debilitating neurologic sequelae [2, 4] .
Local control of brain metastases using radiation with or without surgery, the mainstays of treatment for brain metastases, is critical to prevent neurologic disability, and can potentially improve OS [5] . Historically, radiation for brain metastases has been delivered as whole-brain radiotherapy (WBRT); however, high-dose stereotactic radiosurgery (SRS) achieves comparable OS while decreasing the neurocognitive disability associated with WBRT in patients with limited numbers of brain metastases [6] . Although these advances have improved quality of life, they have not changed the palliative nature of treatment for intracranial metastases. Median survival of patients with triple negative BMBC, for example, remains less than 6 months [7, 8] , indicating a clear need for novel therapeutic strategies.
Both obesity and diabetes have been associated with larger, higher grade tumors with increased metastatic and recurrent potential [9, 10] . Preclinical studies implicate obesity as a driver of a number of the hallmarks of cancer. Obesity-related increases in IGF-1R signaling augment breast cancer cell proliferation and decrease apoptosis [11] . The consequential chronic inflammatory state caused by obesity facilitates immune dysregulation and angiogenesis [12] . Additionally, excess body fat creates an environment conducive to the enhanced glycolytic metabolism in cancer cells [13] .
These metabolic drivers of tumorigenesis become even more relevant within the CNS, where glucose is the sole source of energy. Therefore, tumors that have penetrated the CNS may be more susceptible to manipulations in glucose metabolism [14] . Preclinical research shows that breast cancer cells may alter several metabolic pathways to utilize glucose but minimize production of reactive oxygen species as a means to promote survival and proliferation of intracranial metastasis [15] . The observation in our lab that caloric restriction reduces the likelihood of metastases and therapeutically synergizes with radiation to improve treatment response of both primary tumors and lung metastases in murine models supports the critical role of metabolism in breast cancer [2, 16] . We hypothesized that altered metabolism manifesting as obesity or diabetes would portend a worse prognosis in BMBC patients as compared to those patients who are not obese or diabetic. This retrospective analysis examines the role of obesity as measured by body-mass index (BMI) and the presence or absence of diabetes on clinical outcomes in patients with BMBC treated with either SRS or WBRT.
Methods

Patient selection
This single institution, retrospective cohort study was designed to investigate whether BMI may be prognostic of OS in patients with BMBC who were treated with SRS or WBRT. After IRB approval was obtained, our institution's radiation-specific electronic health record, MOSAIQ® was queried for patients with BMBC treated at Thomas Jefferson University Hospital. Inclusion criteria included only the presence of intracranial metastasis presumed or biopsyproven to be of breast carcinoma origin and subsequent treatment with either SRS or WBRT. No exclusion criteria were identified.
Patient demographics, history of diabetes mellitus, histopathology (including histology type, receptor status, proliferation index), radiology, prior treatment, height and weight, radiotherapy technique, and survival data were collected from the electronic health record. BMI, calculated as weight in kilograms (kg) divided by the square of height in meters, was defined by values at the time of radiographic diagnosis of BMBC. Patients were subsequently divided into two groups: BMI < 25 kg/m 2 and BMI ≥ 25 kg/m 2 . Stable extra-cranial disease was defined as the absence of extra-cranial progression of disease over 3 months prior to the identification of BMBC. Receptor status and histologic grade were defined as previously described by immunohistochemistry and/or fluorescence in situ hybridization [17] . Briefly, tumors were classified as hormone receptorpositive (HR+) if the estrogen or progesterone receptors were detected on ≥ 1% of tumor cells. HER2 status was first scored by immunohistochemistry and categorized from 0 to 3+. Further classification of 2 + results was performed with fluorescence in situ hybridization.
Primary and secondary endpoints
The primary objective of this study was to determine whether BMI and diabetes affect OS in patients with BMBC. The secondary objective was to determine which host factors affect intracranial progression-free survival (PFS) as defined on imaging. Additionally, OS was determined for each tumor subtype including triple negative, HER2+, and HR+ triple negative. To determine the relative prognostic indices between the two groups, breast cancer diseasespecific graded prognostic assessments (GPA) and modified breast-GPA, two validated models for predicting survival in patients with BMBC were calculated as previously described [18, 19] .
Radiation therapy
Radiation was delivered as either whole-brain radiation (WBRT) or stereotactic radiosurgery (SRS) based on physician discretion. Patients who received WBRT had a median number of four lesions. WBRT was delivered with opposed lateral fields planned with CT-based simulation to a median dose of 3000 cGy (range 2700-4750 cGy) in a median number of ten fractions. SRS was delivered either as single fraction or fractionated stereotactic radiosurgery (FSRT) depending on the size and location of the lesion. The median dose for lesions treated with SRS or FSRT was 2100 cGy (range 1200-2800 cGy) with a median number of three brain lesions treated. Target lesions were delineated on pre-treatment MRI with a 1.25 mm cut sequence and iPlan RT® software from Brainlab was used to create treatment plans. Our institutional practice for SRS is to use a maskbased linear accelerator technique for delivery of external beam radiation with 6MV photons. A portion of patients treated in the last 5 years of inclusion were treated with flattening filter-free mode.
Statistical analysis
Statistical analyses were performed using t-tests for continuous variables, Wilcoxon rank-sum test for non-normally distributed variables, and Chi square for categorical variables. Univariate risk factors hazard ratios for death from BMBC were used to generate a full multivariate model. A backwards elimination model selection procedure was implemented to sequentially remove other predictors until all predictors were p < 0.10. All statistical analyses were performed using SPSS, IBM Analytics. Kaplan Meier curves were generated using commercially available Graph Pad Prism® software (La Jolla, CA).
Results
Sample characteristics
Eighty-four consecutive patients with BMBC who were treated with WBRT, SRS, or a combination of the two modalities at Thomas Jefferson University Hospital between December 1, 2003 and March 1, 2016 were identified. No patients were excluded from analysis. Characteristics of the study population are presented in Table 1 . The majority of patients was over the age of 50; however, 38.1% of the population was younger than 50 years, 35.7% had TNBC, 53.5% had a BMI ≥ 25 kg/m 2 , and 20.2% had diabetes. Patients were stratified according to BMI < 25 kg/m 2 versus ≥ 25 kg/m 2 . These groups represented 46.4 and 53.5% of the study population, respectively, and their characteristics at the time of diagnosis of BMBC are presented in Table 1 
Univariate characteristics associated with survival
At the time of analysis, 81 survival events had occurred and median OS was 21.7 months (range 1.2-86.6 months). Factors hypothesized to be associated with OS were analyzed are shown in Table 2 [18, 19] . In support of our hypothesis that obesity and diabetes may worsen prognosis in patients with BMBC, both BMI ≥ 25 kg/m 2 (HR 2.42, p < 0.001) and a diagnosis of diabetes (HR 2.89, p = 0.002) significantly worsened survival. The number of lines of systemic therapy prior to BMBC diagnosis was not significantly associated with OS (HR 1.14, p = 0.388); however, patients who had stable systemic disease (HR 0.77, p = 0.022) and higher KPS (HR 0.98, p = 0.013) had significantly improved OS. While there was a numerical difference in OS between patients who underwent surgical resection vs. those who did not, it was statistically insignificant (HR 0.77, p = 0.226). When comparing receptor subtypes, patients with triple negative tumors had a worse prognosis (HR 2.21, p = 0.001) while survival was better for those who had HR + tumors, regardless of HER2 status (HR 0.61, p = 0.012).
Given that these findings could be confounded by obesity or diabetes-related comorbidities or toxicities, we assessed the incidence of pre-existing or development of peripheral neuropathy, chronic kidney disease (Stages III-V) [20] , and cardiac morbidity, including acute coronary syndrome and left ventricular dysfunction [21] (Supplemental Data, Table 1 ). Overall, these toxicities and comorbidities were relatively uncommon.
Survival data: BMI and diabetes
BMI ≥ 25 kg/m 2 was associated with a significantly shorter median OS from the time of radiographic diagnosis of BMBC (13.7 months vs. 30.6 months; p < 0.001) and intracranial PFS (7.4 vs. 10.9 months; p = 0.049) as shown in the Kaplan-Meier curves Fig. 1a and b. A diagnosis of diabetes was also associated with decreased median OS (11.8 months vs. 26.2 months; p < 0.001) and intracranial PFS (4.5 months vs. 10.3 months; p = 0.001), as shown in Fig. 1c, d . Median OS (p = 0.46) and intracranial PFS (p = 0.22) times were similar between patients with insulin-dependent and non-insulin-dependent diabetes. Despite the association of obesity with diabetes, there is a significant separation of OS curves between non-diabetic and diabetic patients with elevated BMI (p = 0.0497) (Fig. 1e) . However, trends toward decreased intracranial PFS in diabetic patients with BMI ≥ 25 kg/m 2 compared to non-diabetic patients with BMI ≥ 25 kg/m 2 did not reach statistical significance (p = 0.18) (Fig. 1f) .
Furthermore, BMI ≥ 25 kg/m 2 was associated with decreased median OS in all three major molecular subtypes of breast cancer. OS in patients with BMI ≥ 25 kg/ m 2 was significantly worse regardless of histologic subtype; triple negative breast cancer (9.6 months vs. 21.6 months; p = 0.009), HR+ breast cancer (18.5 months vs. 35 .0 months p = 0.013), (Fig. 2a, b) , and HER2+ breast cancer (19.6 months vs. 36.5 months; p = 0.045) (Fig. 2c) . Finally, we assessed the effects of BMI on OS as a continuous rather than a binary variable in the entire cohort. As shown in Fig. 3a , there was a non-zero (p < 0.001) inverse relationship between BMI and OS.
Multivariate analysis
All factors associated with OS to a level of p < 0.10 were incorporated into a multivariate model for overall survival. These included age, BMI, diabetes, KPS, stability of extracranial disease, ER+, or triple negative cancers. A backwards elimination model selection procedure was implemented to sequentially remove other predictors until all predictors were p < 0.05. Despite the insignificance of age (p = 0.167), this variable was retained in the multivariate model. The variable of ER+ breast cancer was dropped from the model, and hazard ratios for the remaining variables are shown in Table 2 .
Discussion
BMBC portends a poor prognosis despite advances in radiation therapy [2, 18, 22, 23] . Obesity has been implicated as a risk factor for metastases and overall poor prognoses and its resultant metabolic dysregulation may promote radioresistance [24, 25] . We hypothesized that obesity and diabetes may be drivers of survival in patients with BMBC treated Fig. 1 The effect of BMI and diabetes on overall survival and intracranial progression-free survival (PFS) among all patients. KaplanMeier OS curves for the entire cohort are shown according to BMI (a). Kaplan-Meier Intracranial PFS curves are shown for the entire cohort according to BMI (b). Kaplan-Meier OS curves for the entire cohort are shown according to diabetes (c). Kaplan-Meier intracranial PFS curves are shown for the entire cohort according to diabetes (d). The impact of diabetes on OS (e) and intracranial PFS (f) is depicted in the Kaplan-Meier curve among patients with BMI ≥ 25. Differences in curves were assessed by the log-rank test factors for death. As expected, triple negative breast cancer patients overall had a worse prognosis, which has been corroborated in previous data [2, 4, 18] . Further, BMI was negatively correlated with OS in all three molecular subtypes of breast cancer: triple negative (p = 0.009), HR+ (p = 0.013), and HER2+ (p = 0.045). While both obesity and BMI have been associated with poor OS in patients with metastatic breast cancer, our finding of reduced local control of irradiated BMBC in these patients appears to represent a novel finding.
In support of this, preclinical studies have shown that obesity, increased caloric intake, and states of insulin resistance enhance cancer cell proliferation, evasion of anti-tumor immunity, and radioresistance [16, 26, 27] . The availability of glucose within the CNS, however, bestows a metabolic advantage upon breast cancer, as it is conducive to the Warburg-like metabolic reprogramming from oxidative phosphorylation toward a glycolytic metabolic preference [15, 28] . IGF-1 availability is also increased in states of obesity and insulin resistance [29] , and activation of the IGF-1R axis has been implicated as a key mediator of breast cancer radioresistance [30] . Thus, "metabolic syndromes" characterized by elevated BMI, diabetes, increased IGF-1 and insulin resistance may account for the poor prognosis we observed in patients with BMI ≥ 25 kg/m 2 and/or diabetes. The possibility also remains that these OS survival outcomes were influenced by an obesity-related or diabetesrelated potentiation of toxicity. In early-stage breast cancer, for example, obesity exacerbates skin toxicity [31] . Within the CNS, radiographic white matter changes, a marker of neurocognitive decline, are prevalent in patients with BMBC treated with WBRT [32, 33] and even more common in patients with hyperglycemia and hypertension [34] . Neurocognitive decline can be a significant contributor to a patient's eligibility for additional systemic therapy and therefore if obese patients experience increased a c b Fig. 2 The effect of BMI on survival according to receptor status. a-c A Kaplan-Meier curve presents OS in patients with a triple negative, b HR+, and c HER2 + breast cancer, according to BMI. Differences in curves were assessed by the log-rank test toxicity and therefore neurocognitive decline, it is possible that they receive fewer lines of systemic therapy than those patients who are not obese [35] [36] [37] . The insulin resistance inherent to obesity and diabetes diabetic also undoubtedly complicates best supportive care with glucocorticoids in managing cerebral edema [38] . Aside from this, obese and diabetic patients are at greater risk of peripheral neurological, cardiac, and renal toxicity, all of which may limit systemic therapy options and confound survival data. Notably, in our cohort, these toxicities were relatively uncommon (Supplemental Data).
Our findings are subject to inherent limitations, the first being its small, retrospective nature of this study. To determine whether the association of BMI with decreased OS was confounded by another prognostic variable, we compared the validated breast-specific GPA and modified-breast specific GPA indexes between the two BMI cohorts [4, 18] , both of which were similar between the two groups. The relatively low number of diabetic patients (n = 17) prevents an assessment of the impact of diabetes among different receptor subtypes as well as the relationship between OS and diabetes-related toxicities and comorbidities. Undoubtedly, the relevance of diabetes and obesity as they pertain to intracranial control and OS will need to be prospectively validated on a larger scale. Second, given the retrospective nature of this study and delivery of care in a tertiary setting, we are unable to report cancer-specific mortality. Increased mortality among overweight, obese, and diabetic patients is a competing risk for death and this is not accounted for in our model OS [39] . However, the inverse relationship between intracranial PFS following radiotherapy is consistent with our hypothesis that metabolic dysfunction can mitigate treatment efficacy.
Regardless of these limitations, these data support the core goal of the American Society of Clinical Oncology to develop therapeutic metabolic interventions in breast cancer [26] , several of which have already been proposed. For example, a secondary analysis of the ALLTO trial suggested a potential benefit and detriment of metformin and insulin, respectively, in diabetic patients with HER2+ cancer [40] . Observational studies have found a decreased risk of breast cancer death associated with statin-use [41, 42] , although no definitive cause-effect relationships have been reported. Preclinical research has demonstrated anti-breast cancer activity in either caloric restriction or intermittent fasting [43] [44] [45] [46] , and we have demonstrated therapeutic synergy between caloric restriction and radiotherapy in animal models [11, 27] . A fundamental concern with the clinical translation of therapeutic caloric restriction, however, is adherence. In 2013, we launched the CaReFOR trial, a pilot study assessing the feasibility of caloric restriction in addition to surgery and radiation in patients with early-stage breast cancer [47] . Given the association of elevated BMI and diabetes with poor OS and local control, we speculate that caloric restriction may benefit patients with BMBC and encourage its incorporation into future trial design.
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